Market Executive Summary

REPORT HIGHLIGHT
The antifungal drugs market is estimated to represent a global market of USD 13.8 billion by 2028 with growth rate of 1.9%. Earlier, serious fungal infections were very uncommon, particularly due to the cool temperature. Fungal infections means usual discomfort or hardly it was the life threatening during those days. However, there has been steady increase in incidence rate of fungal diseases during the past few years. One of the factors aiding the spread of these diseases was to rising number of patient population susceptible to fungal infections. For example, yearly incidence of invasive infections of Candida is estimated at around 400,000 cases per year, of which 98,000 cases are reported in the US alone. This shows the potential threat to human health. Commonly systemic fungal infection is due to yeast-like organism is the widespread among patient population.
Other more serious fungal problems are invasive pulmonary aspergillosis, cryptococcal meningitis or endocarditis, and rhinocerebral mucormycosis. Among which, invasive pulmonary aspergillosis is considered to be the leading cause of death in many countries (developed as well as developing). Patients with compromised immunity, extensive medical stays, catheterization for a long time or under organ transplantation are more susceptible toward these types of infections. Other factors such as growing geriatric population, rising research and development activities, technological advancements and development of novel antifungal therapeutics are expected to surge in demand for uptake of antifungal drugs.
Additionally, growing awareness amongst the patients and healthcare professionals is anticipated to propel the demand for this antifungal agent in coming years. Further, presence of unmet need for safe & effective antifungals to treat antifungal disorders is considered to be a key factor attributing toward the market growth over the forecast period. However, availability of alternative treatment options such as herbal medicines and narrow product pipeline for the treatment are expected to limit the growth of antifungal drugs to treat candidiasis.
Fungal infection treatment could be systemic or topical. Of which, topical antifungal treatment is considered to be the first line treatment therapy for superficial, uncomplicated and localized infections. This treatment therapy offers high efficacy and low adverse event to the patients. On other side, systemic agents are delivered to the body tissues by vascular systems. Oral route is usually considered to be the safe, easy and economical route for antifungal drug delivery. However, patient?s choice involve based on drug formulation and other product variables.
Antifungal drugs are divided in terms of Azoles, Echinocandins, Polyenes, Allylamines and others. Azole antifungal drugs act by inhibiting the enzyme that allows fungi to develop. This segment is considered to be the largest market segment and hold dominant position during the forecast period. Azoles are commercialized by brands such as Noxafil, Vfend, and Diflucan. We understood that although above brands hold larger shares, generic penetration is expected to be high and continues to rise. As of 2017, azoles drug class captured 4,326 million revenue and is expected to grow with 0.1% growth rate. Echinocandins is the highest growing drug class in antifungal treatment, with 4.2% CAGR during the forecast period.
In terms of indication, the market divided as Dermatophytosis, Aspergillosis, Candidiasis and Others. Candidiasis segment hold largest revenue and is expected to maintain its dominant position in future. Regionally, the market analyzed in terms of North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Developed regions accounted for the largest share owing to the rise in research and development activities in this area. North America (U.S.) recorded almost 35% share of the total market in 2017.
Antifungal drugs market is fragmented in nature, characterized by the presence of the several generic products in the treatment. Widespread presence of this infection resulted in dynamic changes in this market. These infections are recurrent in nature and there is limited availability of safe & effective options. These factors are anticipated to propel the research in this field which thereby resulted in high market penetration of new antifungal products in coming years.
Giant players such as Pfizer, Inc., Novartis AG, Sanofi-Aventis, Merck, Bayer AG, and GlaxoSmithKline exhibit their potential in this market. These drug manufacturers are focusing on the development of early and rapid diagnostic options to detect fungal problems. Generic competition in very strong in this market, with more than 60% share of the market captured by generic pharmaceuticals. This leave handful of brand drugs to exhibit its significant position in this market. Increasing generic competition coupled with most competitive environment among key players is considered to rise the barriers for new entrants as well as to new product approval. However, we expect that new approval in brand as well as generic version will continue to show significant role for the market development.
The market size and forecast for each segment has been provided for the period 2014 to 2028, considering 2017 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2017 to 2028 for every reported segment.
The years considered for the study are:
Historical Year ? 2014 & 2017
Base Year ? 2017
Estimated Year ? 2017
Projected Year ? 2028
TARGET AUDIENCE
Traders, Distributors, And Suppliers
Manufacturers
Hospitals
Government and Regional Agencies and Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY TYPES
Azoles
Echinocandins
Polyenes
Allylamines
others
MARKET, BY INDICATION
Dermatophytosis
Aspergillosis
Candidiasis
Others
MARKET, BY REGION
North America
Europe
Asia Pacific
Rest of the World
MARKET, BY COUNTRY
Further Breakdown of The North America Market
U.S.
Canada
Further Breakdown of The Europe Market
Germany
France
Rest of Europe
Further Breakdown of The APAC Market
India
China
Rest of APAC
Further Breakdown of The Rest of the World Market
Middle East and Africa
Latin America